DK1789139T3 - Fumarat af 4-((4-((4-(2-cyanethenyl)-2,6-dimethylphenylamino-2-pyrimidinylaminobenzonitril - Google Patents
Fumarat af 4-((4-((4-(2-cyanethenyl)-2,6-dimethylphenylamino-2-pyrimidinylaminobenzonitrilInfo
- Publication number
- DK1789139T3 DK1789139T3 DK05779369.7T DK05779369T DK1789139T3 DK 1789139 T3 DK1789139 T3 DK 1789139T3 DK 05779369 T DK05779369 T DK 05779369T DK 1789139 T3 DK1789139 T3 DK 1789139T3
- Authority
- DK
- Denmark
- Prior art keywords
- fumarate
- pyrimidinylaminobenzonitrile
- cyanethenyl
- dimethylphenylamino
- amino
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MYPI20043578A MY169670A (en) | 2003-09-03 | 2004-09-02 | Combinations of a pyrimidine containing nnrti with rt inhibitors |
PCT/EP2004/052028 WO2005021001A1 (en) | 2003-09-03 | 2004-09-03 | Combinations of a pyrimidine containing nnrti with rt inhibitors |
EP05101447 | 2005-02-25 | ||
PCT/EP2005/054341 WO2006024667A1 (en) | 2004-09-02 | 2005-09-02 | Furamate of 4-( (4-( (4- (2-cyanoethenyl) -2,6-dimethylphenyl)amino)-2-pyrimidinyl)amino)benzonitrile |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1789139T3 true DK1789139T3 (da) | 2012-07-09 |
Family
ID=38091631
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK05779369.7T DK1789139T3 (da) | 2004-09-02 | 2005-09-02 | Fumarat af 4-((4-((4-(2-cyanethenyl)-2,6-dimethylphenylamino-2-pyrimidinylaminobenzonitril |
Country Status (15)
Country | Link |
---|---|
US (3) | US20090215804A1 (da) |
JP (1) | JP4922937B2 (da) |
AT (1) | ATE550074T1 (da) |
BR (1) | BRPI0514861A (da) |
CR (1) | CR9032A (da) |
DK (1) | DK1789139T3 (da) |
EA (1) | EA011036B1 (da) |
ES (1) | ES2384715T3 (da) |
HK (1) | HK1112862A1 (da) |
HR (1) | HRP20120499T1 (da) |
IL (1) | IL181649A0 (da) |
MX (1) | MX2007002594A (da) |
NI (1) | NI200700069A (da) |
NO (1) | NO339788B1 (da) |
SI (1) | SI1789139T1 (da) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9126949B2 (en) | 2011-04-25 | 2015-09-08 | Hetero Research Foundation | Process for rilpivirine |
AU2020364067A1 (en) * | 2019-10-10 | 2022-03-31 | Axcella Health Inc. | Reduced volume formulations including amino acid entities |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5498419A (en) * | 1994-06-03 | 1996-03-12 | Pars; Harry G. | Fumarate salt of 4-(diethyl-3-(1-methyloctyl)-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran-1-ol, 4-(diethyl-amino) butyric |
JO3429B1 (ar) * | 2001-08-13 | 2019-10-20 | Janssen Pharmaceutica Nv | مشتقات برميدينات مثبطة فيروس الايدز |
MY169670A (en) * | 2003-09-03 | 2019-05-08 | Tibotec Pharm Ltd | Combinations of a pyrimidine containing nnrti with rt inhibitors |
CN100554245C (zh) * | 2002-08-09 | 2009-10-28 | 詹森药业有限公司 | 制备4-[[4-[[4-(2-氰基乙烯基)-2,6-二甲基苯基]氨基]-2-嘧啶基]氨基]苄腈的方法 |
AU2002350719A1 (en) * | 2002-11-29 | 2004-06-23 | Janssen Pharmaceutica N.V. | Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base |
CA2513527C (en) * | 2003-02-07 | 2012-08-14 | Janssen Pharmaceutica N.V. | Pyrimidine derivatives for the prevention of hiv infection |
-
2005
- 2005-09-02 AT AT05779369T patent/ATE550074T1/de active
- 2005-09-02 BR BRPI0514861-8A patent/BRPI0514861A/pt not_active Application Discontinuation
- 2005-09-02 DK DK05779369.7T patent/DK1789139T3/da active
- 2005-09-02 SI SI200531539T patent/SI1789139T1/sl unknown
- 2005-09-02 MX MX2007002594A patent/MX2007002594A/es active IP Right Grant
- 2005-09-02 ES ES05779369T patent/ES2384715T3/es active Active
- 2005-09-02 EA EA200700534A patent/EA011036B1/ru unknown
- 2005-09-02 US US11/574,452 patent/US20090215804A1/en not_active Abandoned
- 2005-09-02 JP JP2007528885A patent/JP4922937B2/ja active Active
-
2007
- 2007-03-01 IL IL181649A patent/IL181649A0/en active IP Right Grant
- 2007-03-01 NI NI200700069A patent/NI200700069A/es unknown
- 2007-03-30 CR CR9032A patent/CR9032A/es not_active Application Discontinuation
- 2007-04-02 NO NO20071720A patent/NO339788B1/no unknown
-
2008
- 2008-02-20 HK HK08101831.3A patent/HK1112862A1/xx unknown
-
2011
- 2011-03-04 US US13/040,465 patent/US20110150996A1/en not_active Abandoned
-
2012
- 2012-06-14 HR HRP20120499TT patent/HRP20120499T1/hr unknown
-
2017
- 2017-12-22 US US15/852,181 patent/US20180116964A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP2008511591A (ja) | 2008-04-17 |
ATE550074T1 (de) | 2012-04-15 |
NO339788B1 (no) | 2017-01-30 |
BRPI0514861A (pt) | 2008-06-24 |
NI200700069A (es) | 2015-12-10 |
EA200700534A1 (ru) | 2007-08-31 |
US20180116964A1 (en) | 2018-05-03 |
US20110150996A1 (en) | 2011-06-23 |
HK1112862A1 (da) | 2008-09-19 |
ES2384715T3 (es) | 2012-07-11 |
JP4922937B2 (ja) | 2012-04-25 |
US20090215804A1 (en) | 2009-08-27 |
HRP20120499T1 (hr) | 2012-07-31 |
EA011036B1 (ru) | 2008-12-30 |
NO20071720L (no) | 2007-04-02 |
SI1789139T1 (sl) | 2012-08-31 |
MX2007002594A (es) | 2007-04-25 |
IL181649A0 (en) | 2007-07-04 |
CR9032A (es) | 2009-07-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FR16C1025I1 (fr) | Sel de 4-[[4-[[4-(2-Cyanoethenyl)-2,6-dimethylphenyl]amino]-2-Pyrimidinyl]amino]benzonitrile | |
ME00191B (me) | Farmaceutske kompozicije koje obuhvataju inhibitor hmg reduktaze | |
HK1174922A1 (en) | Processes for the preparation of 4-[[4-[[4-(2-cyanoethenyl)-2,6- dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile 4-[[4-[[4-(2-)-2,6-]]-2-]] | |
JO2973B1 (en) | Fumarate salt for (alpha-beta-R) -6-bromo-alpha-[2- (methylamino) ethyl-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinoline ethanol | |
WO2009007441A3 (en) | Crystalline form of (e) 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2 pyrimidinyl]amino]benzonitrile | |
PL1632232T6 (pl) | Sól 4-[[4-[[4-(2-cyjanoetenylo)-2,6-dimetylofenylo]amino]-2-pirymidynylo]amino]benzonitrylu | |
UA92469C2 (en) | Fumarate of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl amino benzonitrile | |
ATE541573T1 (de) | Pharmazeutische zusammensetzung enthaltend lapatinib | |
DK1789139T3 (da) | Fumarat af 4-((4-((4-(2-cyanethenyl)-2,6-dimethylphenylamino-2-pyrimidinylaminobenzonitril | |
HRP20110563T1 (en) | Salt of 4[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile |